Biotech Reverse Mergers Reach $7.5 Billion in 2026
Companies are leveraging public listings to secure capital as traditional venture funding for biotech firms tightens.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that increased private equity investment in public biotech firms benefits retail investors?
Biotech firms completed 27 reverse mergers in the first nine months of 2026, totaling $7.5 billion in value. These transactions enabled companies to enter public markets through existing Nasdaq listings as traditional venture funding became less accessible.
Why it matters
The surge in reverse mergers signals a strategic shift in how biopharma companies access capital amid tighter venture investment. This trend highlights the increasing reliance on alternative financial structures to maintain development pipelines.
J.P. Morgan reports 27 reverse mergers in the first three quarters of 2026, with 19 utilizing Private Investment in Public Equity (PIPE) financing, compared to only three of 12 deals using this method in 2025.
The players
J.P. Morgan
A global financial services firm that tracks industry capital flows, M&A activity, and biotech transaction data.
Korsana Biosciences
A biotechnology company that raised $380 million through a reverse merger transaction in 2026.
Velaris Therapeutics
A biotechnology firm that secured $350 million in capital via a reverse merger.
Mentari Therapeutics
A biotechnology developer that utilized a reverse merger to raise $200 million.
Nasdaq
The primary public stock exchange where the majority of these life sciences companies seek listing.
The details
A reverse merger allows a private biotech to gain public status by acquiring an existing Nasdaq-listed company that typically holds few remaining assets. PIPE financing—the sale of equity to select institutional investors—is then used to inject fresh capital into the newly combined entity. This mechanism effectively bypasses the traditional initial public offering process, which requires significantly more time and regulatory scrutiny.
Timeline
2021: 34 reverse mergers recorded.
2025: 12 reverse mergers totaling $9.8 billion.
Q2 2026: Biopharma venture funding hit $9.9 billion.
Q3 2026: Biopharma venture funding totaled $6.7 billion.
January-September 2026: 27 reverse mergers completed.
The Tech Race
The 27 reverse mergers in 2026 move the sector closer to the 2021 peak of 34 deals. This activity follows a period of contraction, reflecting how companies are using public market access to compete for capital.
Companies like Korsana Biosciences, Velaris Therapeutics, and Mentari Therapeutics have gained immediate access to public capital markets to fund their research. Investors and industry participants should monitor these firms for future trial results, as this influx of funding accelerates their development timelines.
The takeaway
The rise of reverse mergers suggests that public market access is becoming a defensive necessity for biotech firms facing lean venture capital environments. Stakeholders should track full-year 2026 investment estimates, which are projected to reach $33 billion, to gauge if this liquidity trend persists into 2027.
Further reading
For broader trends in industry capital, see our Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust that increased private equity investment in public biotech firms benefits retail investors?
